Advanced Filters
noise

Lake Success, New York Clinical Trials

A listing of Lake Success, New York clinical trials actively recruiting patient volunteers.

Found 1,133 clinical trials

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluorouracil (5- FU), paclitaxel and …

18 years of age All Phase 2
M Molly Stewart

Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples

This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (EAC) detection are a guideline-endorsed alternative to endoscopy for BE screening. The Oncoguard …

18 - 90 years of age All Phase N/A
R Robert J Ostfeld, MD, MS

The Impact of Dietary Pattern on Erectile Function

The goal of this study is to determine whether erectile function is impacted by dietary patterns in healthy men with normal erectile function.

18 - 35 years of age Male Phase N/A

Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer

The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors contains enough vesicles to do testing that may help the researchers learn more about their NSCLC.

18 years of age All Phase N/A
A Amanda Huggins

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors

18 years of age All Phase 1
H Hengyi Cao, PhD

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms: Arm 1: …

18 - 60 years of age All Phase N/A

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Myeloid malignancies which include AML (acute myeloid leukemia) and MDS (myelodysplatic syndrome) are cancers of the bone marrow which lead to bone marrow failure. The bone marrow is the place or factory in the body where components of blood such as red cells, platelets and white cells are made. In …

18 years of age All Phase 2
T Trisha Yassear, CCRC

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

18 years of age All Phase 1
S Site Public Contact

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is …

18 - 79 years of age All Phase 2

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).

18 - 85 years of age All Phase 3

Simplify language using AI